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PreclinicalThe somatostatin analog pasireotide and the 11β-hydroxylase inhibitor osilodrostat (LCI699) reduce cortisol
levels by distinct mechanisms of action. There exists a scientiﬁc rationale to investigate the clinical efﬁcacy of
these two agents in combination. This manuscript reports the results of a toxicology study in rats, evaluating
different doses of osilodrostat and pasireotide alone and in combination. Sixty male and 60 female rats were
randomized into single-sex groups to receive daily doses of pasireotide (0.3 mg/kg/day, subcutaneously),
osilodrostat (20 mg/kg/day, orally), osilodrostat/pasireotide in combination (low dose, 1.5/0.03 mg/kg/day;
mid-dose, 5/0.1 mg/kg/day; or high dose, 20/0.3 mg/kg/day), or vehicle for 13 weeks. Mean body-weight gains
from baseline to Week 13 were signiﬁcantly lower in the pasireotide-alone and combined-treatment groups
compared to controls, and were signiﬁcantly higher in female rats receiving osilodrostat monotherapy.
Osilodrostat and pasireotide monotherapies were associated with signiﬁcant changes in the histology and
mean weights of the pituitary and adrenal glands, liver, and ovary/oviduct. Osilodrostat alone was associated
with adrenocortical hypertrophy and hepatocellular hypertrophy. In combination, osilodrostat/pasireotide did
not exacerbate any target organ changes and ameliorated the liver and adrenal gland changes observedwithmono-
therapy. Cmax and AUC0–24h of osilodrostat and pasireotide increased in an approximately dose-proportional
manner.
In conclusion, the pasireotide and osilodrostat combination did not exacerbate changes in target organweight or
toxicity compared with either monotherapy, and had an acceptable safety proﬁle; addition of pasireotide to the
osilodrostat regimen may attenuate potential adrenal gland hyperactivation and hepatocellular hypertrophy,
which are potential side effects of osilodrostat monotherapy.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The investigational oral agent osilodrostat (LCI699) is a potent in-
hibitor of human 11β-hydroxylase (CYP11B1; IC50= 2.5 nM) and aldo-
sterone synthase (CYP11B2; IC50 = 0.7 nM), which are responsible for
catalyzing the ﬁnal steps of cortisol and aldosterone biosynthesis, respec-
tively, in the adrenal cortex (Bassett et al., 2004; Menard et al., 2010;
Calhoun et al., 2011). Given its inhibition of the cortisol biosynthesis; GH, growth hormone; HPA,
owth factor1;sc, subcutaneous;
rtis Institutes for BioMedical
1130B, East Hanover, NJ, USA.
. This is an open access article underpathway, osilodrostat is currently under investigation as a potential
new treatment option for Cushing's syndrome, a rare disorder of chronic
hypercortisolism, and has shown encouraging efﬁcacy and safety in a
proof-of-concept study of 12 patients with Cushing's disease (Bertagna
et al., 2014).
Pasireotide is a multireceptor-targeted somatostatin analog with
high binding afﬁnity to four of the ﬁve somatostatin receptor subtypes
(sst1,2,3 and sst5), with an IC50 of 9.3, 1.0, 1.5, and 0.16 nM for human
sst1, sst2, sst3, and sst5, respectively (Bruns et al., 2002). Activation of
these receptor subtypes, especially sst5, by pasireotide at the pituitary
gland potently suppresses adrenocorticotropic hormone (ACTH) and
growth hormone (GH) secretion (Colao et al., 2012, 2014). ACTH is an
important component of the hypothalamic–pituitary–adrenal (HPA)
axis, which stimulates corticosteroid production by the adrenal glands.
In a large phase III trial, subcutaneous (sc) administration of pasireotidethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Drug doses applied by randomized group.
Group Osilodrostat/pasireotide
dose level (mg/kg/day)
Males
(n)
Females
(n)
Vehicle control 0/0 10 10
Low-dose Osilodrostat/pasireotide 1.5/0.03 10 10
Mid-dose Osilodrostat/pasireotide 5/0.1 10 10
High-dose Osilodrostat/pasireotide 20/0.3 10 10
High-dose osilodrostat 20/– 10 10
High-dose pasireotide –/0.3 10 10
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that was maintained over time (Colao et al., 2012). Based on the results
of this study, a twice-daily sc formulation of pasireotide (Signifor®) has
been approved for the treatment of patients with Cushing's disease in
the United States, Europe, and several other countries (PI, 2012; SPC,
2013).
Pasireotide and osilodrostat have been shown to reduce cortisol
levels through distinct mechanisms of action at different levels of the
HPA axis. Pasireotide inhibits ACTH secretion from the pituitary gland,
while osilodrostat inhibits the biosynthesis of cortisol in the adrenal cor-
tex (Bertagna et al., 2014). Thus, there is a scientiﬁc rationale for inves-
tigating the efﬁcacy of these 2 agents in combination. As the safety
proﬁle of this drug combination has not been established, it is initially
necessary to examine the toxicity proﬁle and potential drug–drug inter-
actions associated with the coadministration of osilodrostat and
pasireotide. This paper reports the results of a 13-week toxicology
study with different doses of osilodrostat and pasireotide, alone and in
combination, in Wistar rats.
Methods
The experiments described in this paper were performed in accor-
dance with the National Animal Welfare guidelines of the US National
Research Council and the Canadian Council on Animal Care. Good Labo-
ratory Practice regulations were observed.
Study design. Sixty male and 60 female rats were randomized in-
to single-sex groups to receive daily doses of vehicle, low-dose
osilodrostat/pasireotide, mid-dose osilodrostat/pasireotide, high-
dose osilodrostat/pasireotide, high-dose osilodrostat monotherapy,
or high-dose pasireotide monotherapy (Table 1). Prior to initiation
of dosing, all animals were weighed, and randomization was strati-
ﬁed by body weight. Rats received their speciﬁed treatment regimen
daily for 13 weeks; the 13-week treatment period was chosen accord-
ing to current European Medicines Agency recommendations (ICH
M3 [R2]). Three female sentinel rats were used for health screening
procedures.
Osilodrostat was administered orally using a plastic gavage tube,
followed by, where applicable, sc injection of pasireotide into the
interscapular area within 5 min of osilodrostat administration. Animals
were dosed at approximately the same time each day, except duringTable 2
Schedule of endpoint collections and study timeline.
Week −1 1 2 3
Cage-side observations Daily (pre-dose and 1 h
Body weighta X x x x
Food consumption X x x x
Ophthalmology X
Clinical pathology (hematology, serum chemistry, urinalysis)
IGF-1
Toxicokinetic evaluations x
Euthanasiab
a Body weight was measured prior to randomization, on Day−1, and weekly thereafter.
b Necropsy, tissue collection, and organ weight measurements were performed on Day 92.designated procedures. Oral and sc routes of administration were
selected for osilodrostat and pasireotide, respectively, as they represent
the intended routes of administration in humans.
The low, mid, and high doses of osilodrostat (1.5, 5, and
20 mg/kg/day) and pasireotide (0.03, 0.1, and 0.3 mg/kg/day) were
considered appropriate based on the results of previous monothera-
py studies in rats (osilodrostat dose range: 0.2–50mg/kg/day, orally;
pasireotide dose range: 0.08–0.24 mg/kg/day, sc; Novartis Pharma
AG, unpublished data); these doses were expected to provide sufﬁ-
cient exposure multiples against human systemic exposure at thera-
peutic doses. Osilodrostat and pasireotide doses of up to 20 and
0.24 mg/kg/day, respectively, were tolerated during two 6-month
monotherapy studies; the no-observed-adverse-effect levels (NOAELs)
for osilodrostat and pasireotide were 2 and 0.024 mg/kg/day, respec-
tively (Novartis Pharma AG, unpublished data).
Compounds and formulation. Osilodrostat was formulated in ultrapure
water for administration by oral gavage. Pasireotide was formulated
with acetate-buffered solution (pH 4.5), acetic acid, and D-mannitol in
sterile water for sc injection. Vehicle control consisted of ultrapure
water for oral gavage and acetate-buffered solution (pH 4.5), acetic
acid, and D-mannitol in sterile water for sc injection. Dosing volumes
were 5 mL/kg for oral gavage (osilodrostat and vehicle) and 1 mL/kg
for sc injection (pasireotide and vehicle). Agents were stored at 4 °C
andprotected from light. For administration of osilodrostat, dosing solu-
tions were removed from the refrigerator and stirred for at least 10min
at room temperature prior to initiation of dosing. Dosing solutions of
pasireotide were removed from the refrigerator and allowed to warm
to room temperature for at least 30 min prior to initiation of dosing.
Animals and housing. Rattus norvegicus, Wistar Hannover Crl:WI (Han),
were 7–8 weeks of age and had body weights of 176–216 g for males
and 123–165 g for females at the start of dosing. Rats were housed
with up to 2 other animals of the same sex and dosing group in polycar-
bonate bins containing appropriate bedding and equipped with an
automatic watering valve. A 12-hour light/dark cycle was in effect,
and rats were housed at a room temperature of 19–25 °C with relative
humidity of 30–70%. Food (PMI Nutrition International Certiﬁed Rodent
Chow No. 5CR4 [14% protein]) and municipal tap water that had been
softened, puriﬁed by reverse osmosis, and exposed to ultraviolet light
were provided ad libitum. There were no known contaminants in the
food or water that interfered with the conduct of the study.
Endpoints and assessments. This study sought to determine the effects of
daily osilodrostat and pasireotide, alone and in combination, on the
pituitary–adrenal axis and to report any other treatment-related toxic-
ities. The toxicokinetic characteristics of osilodrostat and pasireotide
were also determined.
The schedule of study assessments is summarized in Table 2. Cage-
side observations were performed daily pre-dose and 1 h post-dose.
Evaluation of body weight and food consumption was performed at
baseline and weekly thereafter. Ophthalmologic evaluations were4 5 6 7 8 9 10 11 12 13 Day 92
post-dose)
x x x x x x x x x x x
x x x x x x x x x x
x
x x
x
x
x
Fig. 1.Mean body weight over time for male (A) and female (B) rats (from baseline to Week 13; n= 10).
Table 3
Mean (SD) serum IGF-1 levels in male and female rats after 13 weeks of treatment
(n = 10).
Groups Control Low 
dose 
Mid–
dose
High  
dose
Osilodrostat 
alone
Pasireotide 
alone
Males 1030.5
(189.0)
745.3a
(183.1)
658.9b
(141.5)
590.0b
(135.6)
1021.8
(194.2)
548.0b
(145.9)
Females 625.7 
(172.7)
827.7 
(129.1)
776.7 
(198.7)
812.4 
(215.2)
931.4a
(152.3)
590.5 
(162.3)
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Blood and urine samples were collected for assessment of clinical
pathology parameters including hematological assessment, serum
chemistry, and urinalysis in a non-fasting state during Week 4 and at
study end, on Day 92. Insulin-like growth factor 1 (IGF-1) levels were
assessed on Day 92. Blood samples were collected from the jugular
vein during the dosing period (Week 4) and from the abdominal aorta
after isoﬂurane anesthesia at study termination. Toxicokinetic evalua-
tions were performed on Day 1 and Week 11 (2 rats/group/time point).
Animals were euthanized at study end.
Statistical analyses. Results are presented asmean±SD. For comparison
of more than 2 groups, the ANOVA and Dunnett post hoc test were
performed. In the case of heterogeneous group variances, the non-
parametric Kruskal–Wallis and post hoc Dunn test were performed.
Results
At baseline, all animals were healthy and deemed suitable for use in
the study; no health concerns were noted in sentinel animals. No
known circumstances or errors occurred that were considered to affect
the quality or integrity of the study or any interpretations derived from
the data.
In-life observations
No deathswere reported during the 13-week study. No drug-related
clinical signs of toxicity, effects on food consumption, or ocular changes
were observed during the study.No signiﬁcant differenceswere noted inmean baseline bodyweights
between randomized treatment groups for eithermale or female rats. In
general, dose-dependent reduction of body weight gains is associated
with treatment with pasireotide, with effects more pronounced in
males than in females. The mean body weight of male control rats in-
creased from 198.3 ± 9.2 g at baseline to 368.0 ± 25.2 g at Week 13
(meanbodyweight gain, 169.7±25.0 g). Comparedwithmale controls,
mean body weight gains at Week 13 were signiﬁcantly lower for male
rats receiving pasireotide alone (37.1 ± 7.9 g, P≤ 0.001) and in combi-
nation with osilodrostat (low-dose: 69.0 ± 11.5 g, P ≤ 0.01; mid-dose:
52.1 ± 11.4 g, P ≤ 0.001; high-dose: 41.2 ± 8.0 g, P ≤ 0.001; Fig. 1A).
The mean body weight of female control rats increased from 141.6 ±
10.1 g at baseline to 214.3 ± 10.9 g at Week 13 (mean body-weight
gain, 51.7 ± 6.6 g). Mean body-weight gains were signiﬁcantly lower
than those in controls for female rats administered pasireotide alone
(32.5 ± 5.0 g, P ≤ 0.001) and the high-dose osilodrostat/pasireotide
combination (41.0 ± 6.4 g, P ≤ 0.05). By contrast, mean body weight
Table 4
Mean (n=2 rats/group/time point) rat plasma osilodrostat and pasireotide toxicokinetic
parameters when administered in combination.
Dose (mg/kg/day) Males Females
Osilodrostat 1.5 5 20 1.5 5 20
Pasireotide 0.03 0.1 0.3 0.03 0.1 0.3
Osilodrostat AUC0–24h (ng·h/mL)
Day 1 2450 12,700 98,000 2730 15,700 80,400
Day 77 2690 11,500 50,000 3010 13,300 51,600
Osilodrostat Cmax (ng/mL)
Day 1 634 2100 7200 608 2170 5490
Day 77 999 2340 6100 617 2130 4930
Pasireotide AUC0–24h (ng·h/mL)
Day 1 108 365 947 66.1 210 651
Day 77 143 442 1510 79.6 318 888
Pasireotide Cmax (ng/mL)
Day 1 34.4 122 237 27.9 95.4 186
Day 77 61.1 160 293 45.5 146 323
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alone than controls (65.7 ± 11.8 g; P ≤ 0.001; Fig. 1B).
Clinical pathology (hematology, serum chemistry, and urinalysis)
Hematologic changes that were noted in rats receiving osilodrostat
and pasireotide, alone and in combination, were minimal and included
reduced red blood cell volume (decreased mean corpuscular volume)
and decreased reticulocyte count. These changes suggested a slight,
transient decrease in red blood cell production and corresponded with
histologically observed bone marrow hypocellularity in treated male
rats.
Minimal decreases in albumin, globulin, and total protein concentra-
tions corresponded with the observed reductions in body weight. Min-
imal decreases in mean calcium levels were also noted and were
possibly related to the secondary decreases in albumin and/or globulin
levels. Minimal reductions in triglyceride levels in female rats and
mild, non-dose-related decreases in creatine kinase activity in male
rats were attributed to the observed decreases in body weight. Mild
increases in alkaline phosphatase activity were observed in female
rats receiving pasireotide alone and in combination with osilodrostatTable 5
Mean (SD) organ weights for male and female rats at Week 13 (n= 10).
Dose (mg/kg/day)
Osilodrostat 
Pasireotide
–
–
1.5
0.03 0
Males
Pituitary gland  (mg) 10.32 ± 2.20 9.43 ± 1.43 7.91 
Adrenal gland (mg) 45.11 ± 7.86 41.36 ± 6.34 37.47 
Liver (g) 9.85 ±  0.58 9.10 ± 1.11 8.47 
Females
Pituitary gland (mg) 14.32 ± 2.23 14.30 ± 2.66 11.88 
Adrenal gland (mg) 54.44 ± 6.86 58.09 ± 6.73 55.49 
Liver (g) 6.16 ± 0.55 6.13 ± 0.46 5.79 
Ovary/oviduct (mg) 124.00 ± 12.36 139.52 ± 16.55 149.18 at all doses tested; these changes did not correspondwith any histolog-
ical ﬁndings.
In urinalysis, ﬁndings were limited to slight decreases in speciﬁc
gravity and creatinine levels in male rats receiving pasireotide alone,
but were not associated with any microscopic ﬁndings.
Hormonal effects
Signiﬁcant, dose-dependent decreases in IGF-1 levels were noted for
male rats receiving pasireotide alone (P b 0.001) and in combination
with osilodrostat (low dose: P b 0.01; mid-dose: P b 0.001; and high
dose: P b 0.001) (Table 3). In female rats, increases in IGF-1 levels
were not statistically signiﬁcant, except for the osilodrostat mono-
therapy group (P b 0.01).
Low-, mid-, and high-dose groups received osilodrostat and
pasireotide in combination at doses of 1.5/0.03, 5.0/0.1, and 20.0/0.3 mg,
respectively.
Toxicokinetics
On Day 1, an increase in osilodrostat dose from 0.5 to 20 mg/kg/day
in combination with pasireotide (dose range, 0.03–0.3 mg/kg/day)
was accompanied by approximately dose-proportional increases in
maximum plasma concentration (Cmax) and area under the concentra-
tion–time curve from 0 to 24 h (AUC0–24h) for osilodrostat in male and
female rats (Table 4). For each dose group, the osilodrostat AUC0–24h
and Cmax were similar after multiple doses (Day 77) compared with
those after a single dose (Day 1) and were, in general, similar between
sexes.
An increase in pasireotide dose from 0.03 to 0.3 mg/kg/day in com-
bination with osilodrostat (dose range, 0.5–20 mg/kg/day) on Day 1
led to dose-proportional increases in Cmax and AUC0–24h for pasireotide
in male and female rats (Table 4); the Cmax and AUC0–24h of pasireotide
increased slightly after multiple doses compared with those after a
single dose. A slight gender difference was observed in pasireotide
exposure at all doses tested (male/female AUC0–24h ratio, 1.4–1.8).
Toxicokinetic parameters were not assessed for rats administered
osilodrostat or pasireotide alone.5
.1
20
0.3
20
–
–
0.3
± 1.02b 7.96 ± 0.64b 9.78 ± 1.82 8.27 ± 1.76a 
± 4.16a 36.17 ± 5.87a 49.68 ± 7.98 36.15 ± 4.22a 
± 1.25b 8.52 ± 0.98a 10.75 ± 0.82 6.90 ± 0.73c
± 1.65a 11.16 ± 0.97b 13.05 ± 2.21 11.45 ± 1.51b
± 7.09 52.96 ± 7.14 70.02 ± 13.23c 45.85 ± 2.56
± 0.55 6.03 ± 1.19 7.89 ± 0.85c 5.04 ± 0.42b
± 18.15a 155.15 ± 21.67b 193.81 ± 31.90c 106.24 ± 17.01
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After 13 weeks of treatment, differences were noted in the mean
weights of the pituitary and adrenal glands, liver, and ovary/oviduct
compared with the corresponding organs in control rats (Table 5);
similar ﬁndings were noted when mean organ weights were expressed
relative to brain weight (Supplementary Table 1).
At Week 13, mean pituitary weights were signiﬁcantly lower than
controls for male and female rats receiving pasireotide alone (P b 0.05
and P b 0.01, respectively), mid-dose osilodrostat/pasireotide (P b 0.01
and P b 0.05, respectively), and high-dose osilodrostat/pasireotide
(P b 0.01 and P b 0.01, respectively). Decreased mean pituitary weight
corresponded with histologically observed reductions in the cyto-
plasmic mass of acidophil cells in the anterior pituitary of male rats
receiving pasireotide alone (n= 7), mid-dose osilodrostat/pasireotide
(n = 5), and high-dose osilodrostat/pasireotide (n = 9; Fig. 2 and
Table 6). No histological ﬁndings corresponded with decreased mean
pituitary weight in female rats.
In female rats, mean adrenal weight was signiﬁcantly increased rel-
ative to controls after 13 weeks of treatment with osilodrostat alone
(P b 0.001), but not in combination with pasireotide or with pasireotideFig. 2. Decreased cytoplasmic mass of acidophil cells in the pituitary gland of a male rat after 13
sections of pituitary glands frommale rats after 13weeks of treatmentwith vehicle control (A an
20/0.3mg (B andD; images taken using the 2× and 40× objective, respectively). Reduced eosin
D, respectively.alone. Adrenocortical hypertrophy (zona fasciculata) was observed in 4
female rats receiving osilodrostat monotherapy but was not noted
with any other treatment (Fig. 3; Table 6); of these 4 rats, 3 were
found to have enlarged adrenal glands. At Week 13, mean adrenal
weights were signiﬁcantly lower for male rats in the pasireotide alone
(P b 0.05), mid-dose osilodrostat/pasireotide (P b 0.05), and high-dose
osilodrostat/pasireotide (P b 0.05) treatment groups when compared
with controls; no macroscopic or histological changes were associated
with decreased adrenal weight in male rats.
Mean hepatic weight was 25% higher than controls in female rats
after 13 weeks of osilodrostat monotherapy (P b 0.001); a non-
signiﬁcant increase in hepatic weight of approximately 10% was ob-
served inmale rats receiving osilodrostat alone. Osilodrostatmonother-
apy was associated with hepatocellular hypertrophy, which was
histologically observed in all 10 female rats and 6 male rats (Fig. 4;
Table 6). By contrast, mean hepatic weight was reduced in male and fe-
male rats receiving pasireotide monotherapy (P b 0.001 and P b 0.01,
respectively) and in male rats receiving mid-dose osilodrostat/
pasireotide (P b 0.01) and high-dose osilodrostat/pasireotide (P b 0.05);
no histological changes were associated with decreased mean liver
weight.weeks of high-dose osilodrostat/pasireotide treatment. Photomicrographs of histological
d C; images takenusing the2× and 40×objective, respectively) or osilodrostat/pasireotide
ophilia anddecreased cytoplasmicmass of acidophils in the pars distalis are shown in B and
Table 6
Summary of notable histological abnormalities in the liver, pituitary gland, and adrenal gland of rats at Week 13.
Dose (mg/kg/day)
Osilodrostat 
Pasireotide
–
–
1.5
0.03
5
0.1
20
0.3
20
–
–
0.3
Females
Adrenal gland (total examined) 10 10 10 10 10 10
Adrenocortical hypertrophy (n) 0 0 0 0 4 0
Liver (total examined) 10 10 10 10 10 10
Hepatocellular vacuolation (n) 0 0 0 2 7 0
Hepatocellular hypertrophy (n) 0 0 0 0 10 0
Pituitary gland (total examined) 10 9 10 9 10 9
Decreased acidophil cytoplasmic mass (n) 0 0 0 0 0 0
Males
Adrenal gland (total examined) 10 10 10 10 10 10
Adrenocortical hypertrophy (n) 0 0 0 0 0 0
Liver (total examined) 10 10 10 10 10 10
Hepatocellular vacuolation (n) 0 0 0 3 10 0
Hepatocellular hypertrophy (n) 0 0 0 0 6 0
Pituitary gland (total examined) 10 9 10 9 10 9
Decreased acidophil cytoplasmic mass (n) 0 0 5 9 0 7
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niﬁcantly increased in female rats receiving osilodrostat alone (P b 0.001)
and in combination with pasireotide (mid-dose: P b 0.05; high-dose:
P b 0.01). These increases corresponded with follicular degeneration
(with dilatation), which was noted in 6 rats receiving osilodrostat
monotherapy and 3 rats receiving high-dose osilodrostat/pasireotide.
The following additional microscopic changes were also reported
after 13 weeks of treatment: hyperplasia/hypertrophy of vaginal muco-
sa in female rats receiving pasireotide monotherapy (n=7); increased
incidence of hematopoietic hypocellularity in male rats receiving
pasireotide alone (n = 10) and in combination with osilodrostat
(mid-dose: n= 6; high dose: n= 9); and injection-site inﬂammation,
which was reported with pasireotide alone and in combination with
osilodrostat at all doses tested.
Discussion
Corticosterone and cortisol are themost abundant circulating gluco-
corticoids in rats and humans, respectively (Koren et al., 2012). In
humans, pasireotide and osilodrostat reduce cortisol levels via distinct
mechanisms of action; pasireotide suppresses the secretion of ACTHfrom the pituitary gland, whereas osilodrostat inhibits the conversion
of 11-deoxycortisol into cortisol by 11β-hydroxylase in the adrenal
cortex (Colao et al., 2012; Bertagna et al., 2014). In addition to these
cortisol-lowering actions, pasireotide and osilodrostat have been
shown to exert a number of other pharmacological effects, including
pasireotide-mediated suppression of GH secretion from the pituitary
gland (Colao et al., 2012, 2014) and osilodrostat-mediated inhibition
of aldosterone synthase (Menard et al., 2010). The doses of osilodrostat
and pasireotide studied in current combination are biologically relevant
as similar or lower doses were shown to be pharmacologically active in
previous rat studies (Silva et al., 2005; Menard et al., 2014).
In this study, the co-administration of osilodrostat and pasireotide
was generally well tolerated in male and female rats. Osilodrostat
and pasireotide monotherapies were associated with signiﬁcant
changes in histology and the mean weight of several organs, includ-
ing the pituitary glands, liver, adrenal glands, and ovary/oviduct.
None of these target organ changes were exacerbated by combined
osilodrostat/pasireotide treatment, and no new safety concerns were
identiﬁed with combined treatment compared with either mono-
therapy. Furthermore, increases in mean adrenal gland, liver, and
ovary/oviduct weights following osilodrostat monotherapy, and the
Fig. 3.Adrenocortical hypertrophy in the adrenal gland of a female rat after 13weeks of high-dose osilodrostat. Photomicrographs of histological sections of the adrenal glands from female
rats after 13 weeks of treatmentwith vehicle control (A and C; images taken using the 2× and 40× objective, respectively) or osilodrostat 20mg/kg/day (B and D; images taken using the
2× and 40× objective, respectively). Expansion of the zona fasciculata in the adrenal cortex and hypertrophied cells of the zona fasciculata are shown in B and D, respectively.
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were ameliorated by co-administration of pasireotide and osilodrostat
in female rats.
Effects on body weight
The signiﬁcantly lower mean body weight gains reported in both
sexes following administration of pasireotide alone and in combination
with osilodrostat are also consistent with the known inhibitory effects
of pasireotide on GH secretion (Bruns et al., 2002). The signiﬁcantly
higher mean body weight gain in female rats during osilodrostatmono-
therapy is consistent with the results from previous preclinical mono-
therapy studies (Novartis Pharma AG, unpublished data); the exact
mechanism underlying increases in body weight gain in female rats
receiving osilodrostat remains to be determined.
Effects on the pituitary gland
Reductions in pituitaryweightwere observed in ratswith pasireotide
alone and in combination with osilodrostat (mid- and high doses).
Additionally, in male rats, reductions in pituitary weight corresponded
with decreased cytoplasmic mass of acidophils in the anterior pituitary.
These observed effects were consistent with the inhibitory effects of
somatostatin on pituitary gland hormone secretion (Tichomirowa
et al., 2005), and were expected based on the well-characterized effect
of somatostatin analogs on pituitary adenoma volume reduction in
humans (Colao et al., 2008, 2014). In male rats, reductions in pituitaryweight corresponded with decreased cytoplasmic mass of acidophils
in the anterior pituitary. Although decreased pituitary weights were
also observed in females, the lack of microscopic observations in the
pituitary of females is most likely a sequel of the presence of fewer
somatotrophs in females (Stefaneanu and Kovacs, 1994).
Effects on the adrenal glands
Increases inmean adrenalweight in female rats receiving osilodrostat
monotherapy were associated with the development of adrenocortical
hypertrophy (zona fasciculata); this histological phenotype has been
previously noted in 11β-hydroxylase null mice (Mullins et al., 2009).
The development of adrenocortical hypertrophy may result from accu-
mulation of cholesterol and steroid precursors due to inhibition of adre-
nocortical steroid biosynthesis by osilodrostat or, alternatively, represent
a trophic effect of increased pituitary production of ACTH in the absence
of normal negative feedback by glucocorticoids (Harvey and Sutcliffe,
2010). The lack of either adrenocortical hypertrophy or increases in adre-
nal gland weight in female rats receiving osilodrostat in combination
with pasireotide could be explained by the known inhibitory effect of
pasireotide on ACTH secretion (Hoﬂand et al., 2005).
Effects on the liver
Increases in hepatic weight reportedwith osilodrostat monotherapy
correlated with hepatocellular hypertrophy. The development of hepa-
tocellular hypertrophy may result from lipid substrate accumulation in
Fig. 4.Hepatocellular vacuolation with or without hypertrophy inmale rats after 13 weeks of treatment. Photomicrographs of histological sections of livers frommale rats after 13 weeks of
treatmentwith vehicle control (A and B), osilodrostat/pasireotide 20/0.3mg/kg/day (C andD), and osilodrostat 20mg/kg/day (E and F); images A, C, andEwere taken using the 2× objective
and images B, D, and F were taken using 20× objective. Hepatocellular vacuolation without and with hypertrophy is shown in C, D, E, and F, respectively.
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aldosterone synthase by osilodrostat. The absence of increases in liver
weight and hepatocellular hypertrophy in animals treatedwith a combi-
nation of osilodrostat and pasireotide could be explained by the inhibi-
tion of GH and, subsequently, IGF-1 secretion by pasireotide, leading to
a reduction in the known hypertrophic effect of both growth factors
(Bruns et al., 2002). Indeed, levels of IGF-1, the primary mediator of the
effects of GH, were signiﬁcantly reduced in male rats receiving
pasireotide alone and in combination with osilodrostat, but not in
those receiving osilodrostat alone. IGF-1 levels tended to increase in all
female rat treatment groups, these increases were of lesser magnitude
in combination treatment groups compared with osilodrostat alone. Itis noted that the effect of pasireotide on IGF-1 reduction is less pro-
nounced in female rats. This is consistent with the sexually dimorphic
differences in the regulation of GH and somatostatin in rats(Wehrenberg
andGiustina, 1992). Sexually dimorphic differences of effects on IGF-1 by
pasireotide were also observed in previous toxicology studies in rats
(Novartis: unpublished data).
Effects on other organs
Increases in mean ovary/oviduct weight and the histological ﬁnd-
ings of follicular degeneration (with dilatation) with osilodrostat
alone and in combination with pasireotide (mid- and high-doses)
232 L. Li et al. / Toxicology and Applied Pharmacology 286 (2015) 224–233may be attributable to the inhibitory effect of osilodrostat on aromatase
activity (IC50 for human enzyme, 1.7 μM; Novartis Pharma AG, unpub-
lished data), which is responsible for catalyzing the conversion of
testosterone into estradiol (Nunez et al., 1996). It is also possible that
the effects were contributed by Cyp11b1 inhibition, as Cyp11b1 null
mice also had abnormal ovaries, which contained pre-ovulatory follicles
but no clearly deﬁned corpora lutea, and the ovary was ﬁlled with lob-
ular amorphous cells, likely nonsecreting luteinized granulosa cells
(Mullins et al., 2009).
Although no histological or mean weight changes for the heart were
reported in this study, it is important to note that pasireotide has been
shown to cause QTc prolongation in clinical settings (Breitschaft et al.,
2014), whereas preclinical studies of osilodrostat have identiﬁed dose-
related QTc prolongation in monkeys (Novartis Pharma AG, unpub-
lished data). It is, therefore, necessary to establish the cardiac safety
proﬁle of pasireotide and osilodrostat in combination before the combi-
nation therapy can be applied to the broader patient population.
Toxicokinetics of pasireotide and osilodrostat
Toxicokinetic parameters were not assessed for rats administered
osilodrostat or pasireotide alone; however, the overall plasma expo-
sure of osilodrostat observed in this study is consistent with the
results obtained from previous oral toxicology studies of osilodrostat
monotherapy (1–50 mg/kg/day for 4 weeks, 0.5–50 mg/kg/day for
13weeks, and 0.2–20mg/kg/day for 26weeks; Novartis Pharma AG, un-
published data). Similarly, the overall exposure results for pasireotide in
this study are consistentwith the results observed in a previous 26-week
chronic toxicity study in rats subcutaneously dosed with pasireotide
alone at doses of 0.008, 0.024, 0.08, and 0.24 mg/kg/day (Novartis
Pharma AG, unpublished data). These ﬁndings suggest that the co-
administration of pasireotide with osilodrostat did not alter rat plasma
osilodrostat or pasireotide toxicokinetics compared with osilodrostat or
pasireotide alone. Although osilodrostat may regulate the activity of
P450 enzymes, the effect of osilodrostat on themetabolismof pasireotide
is not expected since pasireotide was relatively stable in vivo and in vitro
in terms of drug metabolism in rat and human (Lin et al., 2013). Addi-
tionally, any potential amelioration of the effects of either drug on target
organs could not be attributed to decreased exposure to osilodrostat or
pasireotide.
Conclusions
The combination of pasireotide and osilodrostat in rats did not
change the toxicity proﬁle and plasma exposure seen during admin-
istration of either agent alone, whereas the addition of pasireotide to
the osilodrostat regimen may attenuate potential adrenal gland hyper-
trophy and hepatocellular hypertrophy. As such, this study suggests
that the combination of pasireotide and osilodrostat has an acceptable
safety proﬁle. However, other safety concerns, in particular effects on
QT interval, should also be considered prior to using the pasireotide
and osilodrostat drug combination in humans.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.taap.2015.05.004.
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